Online inquiry

IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1831MR)

This product GTTS-WQ1831MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CFD gene. The antibody can be applied in Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001317335.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1675
UniProt ID P00746
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ1831MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11033MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MCLA-128
GTTS-WQ10656MR IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY-3819253
GTTS-WQ8523MR IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Hu3F8
GTTS-WQ7609MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ10816MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA M7824
GTTS-WQ2402MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 110
GTTS-WQ2739MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG-139
GTTS-WQ8500MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA hu1124
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW